Solution reagent kit TruSight

for researchfor DNA sequencingfor cancers

Developed in collaboration with cancer genomics experts, these predesigned, ready-to-use oligos enable researchers to sequence a variety of genes and single nucleotide polymorphisms (SNPs) previously linked to cancer predisposition. Targets 94 genes and 284 SNPs associated with a predisposition towards cancer TruSight Cancer includes genes associated with both common (e.g., breast, colorectal) and rare cancers. In addition, the set includes 284 SNPs found to correlate with cancer through genome-wide association studies (GWAS). Content selection was based on expert curation of the scientific literature and other high-quality resources. The TruSight Cancer sequencing panel provides custom oligos targeting identified regions of interest. Sufficient product is supplied for four enrichment reactions. TruSight Cancer is compatible with TruSight Rapid Capture. TruSight Cancer Sample Datasets 6 human reference samples were prepared using the TruSight Cancer sequencing panel. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 100 bp read length configuration with dual indexing. The total yield was 5.2 Gb with 95.8% of bases at or above Q30. Specifications Assay time - 1.5 days Cancer type - Pan-cancer Content specifications - Fixed set of probes that enrich for 94 genes and 284 SNPs associated with common and rare cancers. Description - Germline mutation detection research for common and rare cancers. Hands-on time - 5 hr Input quantity - 50 ng DNA Instruments - MiSeq System, NextSeq 550 System, MiSeqDx in Research Mode, MiniSeq System, NextSeq 500 System Method - Targeted DNA sequencing, Target enrichment Multiplexing - Up to 96-plex